Biosimilar deal as patents expire


Budapest/Tokyo – Hungary’s largest drugmaker Gedeon Richter Nyrt. has secured access to the Japanese market for its biosimilar pipeline. In mid-December, Richter CEO Erik Bogsch announced his company had signed a long-term licensing and collaboration agreement with Japan’s Mochida Pharmaceutical Co. Ltd. Under the terms of the agreement, Mochida will contribute to the development costs of Richter’s bio­similar products, which are expected to hit the market in 2015. In return, it will receive exclusive rights for the marketing and distribution of the portfolio in Japan. Mochida will also participate in product development if special market-related development criteria are required in Japan. Following the launch of the products there, further sales-related royalties will become payable to Richter. Gedeon Richter’s management began setting up its biosimilar business in 2006. The firm currently runs a biomanufacturing plant in Budapest, and has invested a27.8m in the construction of a mammalian and insect cell manufacturing facility in Debrecen. It is slated to commence production of biosimilar and biosimilar antibody lots for clinical testing in 2012. The Hungarian firm has not provided any information about which products are currently under development, saying only that the focus will be on oncology and immunology. Patents for important recombinant insulins (Byetta, Humalog, Lantus), TNF blockers (Enbrel), Erythropoietins (Epogen, Neupo­gen) and monoclonal antibodies (Remicade, Rituxan, Herceptin, Tysabri) will expire by 2015. By then, business research sources like Global Industry Analysts expect the bio­similar market to reach the US$2bn mark.



It was a great month for Gedeon Richter Nyrt. (Budapest). At the beginning of February, Hungary’s largest drugmaker announced positive outcomes for two late-stage Phase III trials. In a study sponsored by development partner...



Budapest/Macclesfield – UK-headquartered global ADME-Tox specialist Cyprotex plc has partnered up with Solvo Bio­tech sro to provide the Hungarian firm’s drug transporter assays to its customers in the bio­pharmaceutical...



Budapest/Kraków – In July, illegally planted genetically modified crops made headlines in Hungary, where GMO acreage is banned. Up to 0.1% GMO maize products from Monsanto and Pioneer were discovered at four sites (near...



Budapest – Hungarian vaccine developer Genetic Immunity Kft. (GI) has secured a cash injection of US$25m by signing an agreement with the Budapest-based technology commercialisation company Power of the Dream Ventures, Inc. The...



Budapest – Richter Group has bagged Swiss gynecology and infertility specialist Preg­Lem Holding SA in a 100 % equity stake worth up to EUR 359m. Hungary’s largest drugmaker expects PregLem’s lead candi­date Esmya as...



Budapest – Hungary’s largest drugmaker Gedeon Richter Ltd. and US partner Forest Laboratory said that a Phase II clinical trial of their orally active drug cariprazine (RGH-188) for bipolar depression produced no “statistically...



Budapest – New results from researchers at the Department of Pathology and Experimental Cancer Research in Budapest suggest that expression of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) on the surface of chronic...



Budapest – ChemAxon, a specialist for chemical informatics software for the life sciences industry, has entered into an agreement with Pfizer. Under the terms of the agreement, Chemaxon will provide its Markush searching and...



Budapest/Zug/Edinburgh – Swiss/Hungarian antibody specialist ImmunoGenes has inked a collaboration and license agreement with the Scottish Roslin Institute to develop specialised sheep that use ImmunoGenes’ proprietary technology...

Displaying results 1 to 10 out of 89

1-10 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues